Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$18.54 USD

18.54
3,634,555

-0.42 (-2.22%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $16.40 -2.14 (-11.54%) 4:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the most recent trading session, Adma Biologics (ADMA) closed at $19.50, indicating a -1.37% shift from the previous trading day.

Zacks Equity Research

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Zacks Equity Research

Adma Biologics (ADMA) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal

by Zacks Equity Research

Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.

Zacks Equity Research

Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $19.44, denoting a -0.26% change from the preceding trading day.

Zacks Equity Research

Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market

by Zacks Equity Research

PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.

Zacks Equity Research

Adma Biologics (ADMA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Adma Biologics (ADMA) stood at $19.98, denoting a +1.22% change from the preceding trading day.

Ekta Bagri headshot

ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?

by Ekta Bagri

ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.

Zacks Equity Research

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYC

Zacks Equity Research

Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why Momentum in Adma Biologics (ADMA) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Zacks Equity Research

Adma Biologics (ADMA) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zacks Equity Research

ADMA Biologics Inc (ADMA) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYX

Abhinab Dasgupta headshot

Beat the Market Like Zacks: CareDx, Fair Isaac, 3M in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.

Zacks Equity Research

Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

Here's What Could Help Adma Biologics (ADMA) Maintain Its Recent Price Strength

by Zacks Equity Research

Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYX

Ekta Bagri headshot

ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?

by Ekta Bagri

The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.

Zacks Equity Research

Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Zacks Equity Research

Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.